Business Context and Reporting Period
Xilio Therapeutics, Inc. (XLO) is a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies. This Form 10-Q covers the quarterly period ended September 30, 2024. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. As of November 1, 2024, 43,958,074 shares of common stock were outstanding.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $2.3 million | $0 | $4.6 million | $0 |
| Net Loss | $(14.0) million | $(16.7) million | $(45.1) million | $(58.7) million |
| Operating Expenses | $17.0 million | $17.4 million | $51.6 million | $61.0 million |
| Cash and Cash Equivalents (Sep 30, 2024) | $61.3 million | |||
| Accumulated Deficit (Sep 30, 2024) | $(370.7) million | |||
| Deferred Revenue (Sep 30, 2024) | $34.5 million |
Liquidity: The company reported a net cash increase of $16.7 million for the nine months ended September 30, 2024, driven primarily by financing activities. Operating cash flow was negative $4.2 million for the period.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $2.3 million in license revenue for Q3 2024 and $4.6 million for the nine months ended September 30, 2024, derived from a license agreement and stock purchase agreement with Gilead Sciences, Inc. No revenue was recognized in the comparable 2023 periods.
- Expense Reduction: Total operating expenses decreased by $9.4 million year-over-year for the nine-month period. Research and development expenses declined by $8.0 million, and general and administrative expenses decreased by $2.3 million, largely due to a workforce reduction and strategic portfolio reprioritization in March 2024.
- Restructuring: The company recognized $0.9 million in restructuring charges during the nine months ended September 30, 2024, related to employee severance and benefits. A credit of $0.04 million was recorded in Q3 2024 due to a change in estimate.
- Debt Repayment: The company repaid all amounts outstanding under its loan agreement with Pacific Western Bank in the first quarter of 2024, eliminating related interest expense.
Guidance, Outlook, and Risks
Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. As of September 30, 2024, cash and cash equivalents of $61.3 million are projected to fund operations only through the end of the second quarter of 2025. The company plans to raise additional capital through equity or debt financings, collaborations, or licensing transactions.
Strategic Developments:
- Gilead Partnership: Xilio granted Gilead an exclusive global license for XTX301 (IL-12). Xilio received $30.0 million upfront and approximately $16.8 million in gross proceeds from private placements. Xilio is eligible for up to $600.7 million in additional contingent payments.
- Roche Collaboration: A clinical trial collaboration with F. Hoffmann-La Roche Ltd. is ongoing for vilastobart (XTX101) in combination with atezolizumab. Initial Phase 2 data is expected in Q4 2024.
- Portfolio Reprioritization: The company discontinued further investment in XTX202 as a monotherapy in Q1 2024.
Risks and Contingencies:
- Nasdaq Compliance: The company received a deficiency letter from Nasdaq regarding its stock price closing below $1.00 per share for 30 consecutive business days. It has until March 10, 2025, to regain compliance or risk delisting.
- Capital Requirements: Failure to secure additional capital may force further cost reductions, delays in R&D, or strategic alternatives such as asset divestiture.
- Manufacturing Dependence: The company relies on WuXi Biologics in China for manufacturing, exposing it to geopolitical and supply chain risks.
Investor Verification Checklist
- Verify the timeline and sufficiency of the company's plan to raise additional capital to extend its runway beyond Q2 2025.
- Monitor the status of the Nasdaq deficiency notice and any potential reverse stock split or other actions to regain compliance.
- Review the progress of the Gilead partnership, specifically the timing of the potential $75.0 million transition fee and subsequent milestone payments.
- Assess the impact of the discontinued XTX202 program on the overall pipeline and future R&D burn rate.
- Confirm the status of the Phase 2 clinical trial for vilastobart in combination with atezolizumab and the anticipated data readout in Q4 2024.